Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy
Table 1
Frequency distribution of ABCG2 genotypes and their associations with the risk of developing breast carcinoma.
Genotypes
Cases Number (%)
Controls† Number (%)
Adjusted OR (95% CI)
ABCG2 G34A
GG
554 (47.4)
646 (51.9)
1 (reference)
GA
497 (42.5)
494 (39.7)
0.066
1.171 (0.990–1.386)
AA
118 (10.1)
104 (8.4)
0.051
1.329 (0.998–1.770)
GA/AA
615 (52.6)
598 (48.1)
0.026
1.199 (1.022–1.406)
G allele
1605 (68.65)
1786 (71.8)
1 (reference)
A allele
733 (31.35)
702 (28.2)
0.016
1.163 (1.028–1.316)
ABCG2 C421A
CC
528 (45.2)
598 (48.1)
1 (reference)
CA
509 (43.5)
535 (43.0)
0.397
1.076 (0.909–1.273)
AA
132 (11.3)
111 (8.9)
0.033
1.352 (1.024–1.785)
CA/AA
641 (54.8)
646 (51.9)
0.155
1.123 (0.975–1.318)
C allele
1565 (66.94)
1731 (69.6)
1 (reference)
A allele
773 (33.06)
757 (30.4)
0.048
1.130 (1.001–1.276)
Haplotypes
G34A G-C421A C
967 (41.2)
1281 (51.5)
0.001
0.660 (0.589–0.740)
G34A A-C421A C
603 (25.7)
469 (18.8)
0.001
1.491 (1.300–1.709)
G34A G-C421A A
643 (27.4)
505 (20.3)
<0.001
1.484 (1.299–1.696)
G34A A-C421A A
133 (5.7)
233 (9.4)
<0.001
0.580 (0.465–0.723)
OR indicates odds ratio; CI, confidence interval. †The observed genotype frequency among individuals in the control group was in agreement with Hardy-Weinberg equilibrium (: = 0.483, for ABCG2 G34A; = 0.378, for ABCG2 C421A). ‡ values were calculated from 2-sided chi-square tests for either genotype distribution or allele frequency. Adjusted OR and 95% CI values were calculated by unconditional logistic regression adjusted for age and menopausal status.
